Volume 10,Issue 7
Dyslipidemia is a common metabolic complication after kidney transplantation, affecting 75-95% of recipients. Increasing evidence links post-transplant lipid abnormalities to graft dysfunction and eventual graft loss. However, studies on conventional lipid markers have reported inconsistent associations with transplant outcomes. Emerging lipid indicators may better reflect the burden of atherogenic lipoproteins and provide additional value for risk stratification after transplantation. This review summarizes current evidence on the epidemiology, mechanisms, graft outcome associations, and management of dyslipidemia in kidney transplant recipients, with a focus on postoperative monitoring and prognostic assessment.